文献速递系统性红斑狼疮

皮下贝利尤单抗在抗双链DNA阳性、低补体血症系统性红斑狼疮患者中的疗效与安全性

Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2018-06-15

BEL112341研究纳入836例中重度SLE患者,其中356例基线低补体血症且抗dsDNA阳性,随机2:1接受每周皮下贝利尤单抗200mg或安慰剂联合标准治疗52周。贝利尤单抗组SRI-4应答率64.6% vs 安慰剂组47.2%(P=0.0014),严重复发发生率14.1% vs 31.5%,激素减量比例20.7% vs 11.4%(P=0.0844),不良事件两组相似。

要点

  • 低补体且抗dsDNA阳性SLE患者中,皮下贝利尤单抗200mg每周一次提高52周SRI-4应答率。
  • 贝利尤单抗组严重复发发生率低于安慰剂组(14.1% vs 31.5%)。
  • 第40-52周激素减量≥25%至≤7.5mg/天的患者比例两组差异未达统计学显著(P=0.0844)。

核心结论

  • 在低补体血症且抗dsDNA阳性的SLE患者中,每周皮下贝利尤单抗200mg较安慰剂显著改善SRI-4应答、降低严重复发发生率并减少激素使用。
  • 与总体ITT人群相比,该亚组观察到获益更大的趋势。
  • 不良事件与贝利尤单抗已知安全性特征一致。

研究设计与样本

  • III期双盲安慰剂对照研究(BEL112341;ClinicalTrials.gov标识NCT01484496)。
  • 纳入中重度SLE患者(SELENA-SLEDAI评分≥8),随机2:1接受每周皮下贝利尤单抗200mg或安慰剂联合标准SLE治疗52周。
  • ITT人群836例,其中基线低补体血症且抗dsDNA阳性者356例(安慰剂组108例,皮下贝利尤单抗200mg组248例)。

主要发现

  • 贝利尤单抗组SRI-4应答率64.6% vs 安慰剂组47.2%(P=0.0014)。
  • 贝利尤单抗组严重复发发生率14.1% vs 安慰剂组31.5%(SELENA-SLEDAI复发指数)。
  • 第40-52周激素减量≥25%至≤7.5mg/天的患者比例贝利尤单抗组20.7% vs 安慰剂组11.4%(P=0.0844)。
  • 不良事件两组相似。

关键数值与推荐

  • 基线低补体血症定义为C3<90 mg/dl和/或C4<10 mg/dl。
  • 基线抗dsDNA阳性定义为≥30 IU/ml。
  • 主要终点为第52周SRI-4应答率。
  • 次要终点为至严重复发时间和第40-52周激素剂量减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti-double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. METHODS: In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA-SLEDAI] score ≥8) were randomized (2:1) to receive weekly subcutaneous (SC) belimumab 200 mg or placebo, plus standard SLE therapy, for 52 weeks. The primary end point was SLE Responder Index 4 (SRI-4) response rate at week 52. Secondary end points were time to severe flare and reduction in corticosteroid dose (weeks 40-52). Safety was assessed throughout. RESULTS: Of the 836 patients in the intent-to-treat (ITT) population, 356 were hypocomplementemic and anti-dsDNA positive at baseline (108 in the placebo group and 248 in the SC belimumab 200 mg group). Compared with placebo, the belimumab group contained more SRI-4 responders (47.2% versus 64.6%; P = 0.0014), had a lower incidence of severe flare according to the SELENA-SLEDAI flare index (31.5% versus 14.1%), and had a greater percentage of patients who reduced corticosteroid dosage by ≥25% to ≤7.5 mg/day during weeks 40-52 (11.4% versus 20.7%; P = 0.0844). Adverse events (AEs) were similar between treatment groups. CONCLUSION: Our findings indicate that in hypocomplementemic, anti-dsDNA-positive SLE patients, weekly SC belimumab 200 mg significantly improves SRI-4 response, decreases severe flare incidence, and reduces corticosteroid use versus placebo; a trend toward greater benefit compared with the overall ITT population was observed. AEs were consistent with the known safety profile of belimumab.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Doria A, Stohl W, Schwarting A, et al. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018. PMID: 29671280. doi:10.1002/art.40511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。